NSAIDs are first line therapy for patients with axial spondyloarthritis and are recommended to be taken continuously in patients with active disease, but their ability to affect radiographic disease progression has been uncertain. Does a new meta-analysis shed light on this matter, or is it too soon to tell?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities
Rheumatology and Therapy Open Access 18 December 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zhang, J. R., Pang, D. D. & Dai, S. M. Non-steroidal anti-inflammatory drugs are unlikely to inhibit radiographic progression of ankylosing spondylitis: a systematic review. Front. Med. 6, 214 (2019).
Wanders, A. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 52, 1756–1765 (2005).
Kroon, F. et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann. Rheum. Dis. 71, 1623–1629 (2012).
Sieper, J. et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann. Rheum. Dis. 75, 1438–1443 (2016).
Molnar, C. et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann. Rheum. Dis. 77, 63–69 (2018).
Braun, J. et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70, 896–904 (2011).
Lisowska, B., Kosson, D. & Domaracka, K. Lights and shadows of NSAIDs in bone healing: the role of prostaglandins in bone metabolism. Drug Des. Devel Ther. 12, 1753–1758 (2018).
Varkas, G. et al. Brief report: six-week treatment of axial spondyloarthritis patients with an optimal dose of nonsteroidal antiinflammatory drugs: early response to treatment in signal intensity on magnetic resonance imaging of the sacroiliac joints. Arthritis Rheumatol. 68, 672–678 (2016).
Ramiro, S. et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann. Rheum. Dis. 73, 1455–1261 (2014).
de Koning, A. et al. Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. Ann. Rheum. Dis. 77, 293–299 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Braun, J., Baraliakos, X. Do NSAIDs affect radiographic progression in axial SpA?. Nat Rev Rheumatol 16, 9–10 (2020). https://doi.org/10.1038/s41584-019-0341-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0341-4
This article is cited by
-
The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities
Rheumatology and Therapy (2024)